Pasar al contenido principal

COMBATIR EL DOLOR EVITANDO LOS EFECTOS SECUNDARIOS ADICTIVOS ACTUANDO SELECTIVAMENTE SOBRE LOS HETEROMEROS DEL RECEPTOR MU-OPIOIDE

PID2020-113938RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design of Small Non-Peptidic Ligands That Alter Heteromerization between Cannabinoid CB and Serotonin 5HT Receptors

  • Matsoukas, Minos-Timotheos|||0000-0002-4642-8163
  • Ciruela-Jardí, Marc|||0009-0001-9920-8789
  • Gallo, Maria|||0000-0001-9099-7235
  • Ferré, Sergi|||0000-0002-1747-1779
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Casadó, Vicent|||0000-0002-1764-3825
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Moreno, Estefanía|||0000-0002-2491-5753
Activation of cannabinoid CB receptors (CBR) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CBR and the serotonin 5HT receptor (5HTR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CBR, which are predicted to bind 5HTR and alter the stability of the CBR-5HTR heteromer, have been shown to avert CBR agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CBR-5HTR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CBR-5HTR heteromer, opening new perspectives for in vivo studies.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Design of small non-peptidic ligands that alter heteromerization between cannabinoid CB1 and serotonin 5HT2A receptors

  • Matsoukas, Minos-Timotheos
  • Ciruela Jardí, Marc
  • Gallo, María, 1989-
  • Ferré, Sergi
  • Andreu Martínez, David
  • Casadó, Vicent
  • Pardo, Leonardo
  • Moreno, Estefanía
Activation of cannabinoid CB1 receptors (CB1R) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CB1R and the serotonin 5HT2A receptor (5HT2AR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CB1R, which are predicted to bind 5HT2AR and alter the stability of the CB1R-5HT2AR heteromer, have been shown to avert CB1R agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CB1R-5HT2AR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CB1R-5HT2AR heteromer, opening new perspectives for in vivo studies., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (projects PID2020-113938RB-I00, PID2022-140912OB-I00, and PID2023-146914OB-I00) and Generalitat de Catalunya (2021-SGR-00230 and 2021-SGR-00304). S.F. is funded with the intramural funds of the National Institute on Drug Abuse (ZIA DA000493). Work at MELIS-UPF is supported by the MCIN “María de Maeztu” program for units of excellence in R&D (CEX2018-000792-M). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by the Barcelona Supercomputing Center (RES-BCV-2024-2-0002).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The CB 1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

  • Costas-Insua, Carlos
  • Hermoso-López, Alba
  • Moreno, Estefanía
  • Montero-Fernández, Carlos
  • Álvaro-Blázquez, Alicia
  • Maroto, Irene B.
  • Sánchez-Ruiz, Andrea
  • Diez-Alarcia, Rebeca
  • Blázquez, Cristina
  • Morales, Paula
  • Canela, Enric I.
  • Casadó, Vicent
  • Urigüen, Leyre
  • Perea, Gertrudis
  • Bellocchio, Luigi
  • Rodríguez-Crespo, Ignacio
  • Guzmán, Manuel
Cereblon/CRBN is a substrate-recognition component of the Cullin4A-DDB1-Roc1 E3 ubiquitin ligase complex. Destabilizing mutations in the human CRBN gene cause a form of autosomal recessive non-syndromic intellectual disability (ARNSID) that is modelled by knocking-out the mouse Crbn gene. A reduction in excitatory neurotransmission has been proposed as an underlying mechanism of the disease. However, the precise factors eliciting this impairment remain mostly unknown. Here we report that CRBN molecules selectively located on glutamatergic neurons are necessary for proper memory function. Combining various in vivo approaches, we show that the cannabinoid CB 1 receptor (CB 1 R), a key suppressor of synaptic transmission, is overactivated in CRBN deficiency-linked ARNSID mouse models, and that the memory deficits observed in these animals can be rescued by acute CB 1 R-selective pharmacological antagonism. Molecular studies demonstrated that CRBN interacts physically with CB 1 R and impairs the CB 1 R-G i/o -cAMP-PKA pathway in a ubiquitin ligase- independent manner. Taken together, these findings unveil that CB 1 R overactivation is a driving mechanism of CRBN deficiency- linked ARNSID and anticipate that the antagonism of CB 1 R could constitute a new therapy for this orphan disease., This work was supported by the Spanish Ministerio de Ciencia e Innovación (MICINN/FEDER; grants PID2021-125118OB-I00 to MG, PID2020-113938RB- I00 to EM and VC, PID2019-106579RB-I00 and PID2022-142617NB-I00 to GP, and PID2019-106404RB-I00 to LU), as well as by the Generalitat de Catalunya (grant 2021-SGR-00230 to EM and VC). LB was supported by INSERM. CC-I and IBM were supported by contracts from the Spanish Ministerio de Universidades (Formación de Profesorado Universitario Program, references FPU16/02593 and FPU15/01833, respectively). CC-I was also supported by an EMBO short-term fellowship (reference STF-8930). We are indebted to Dr. Benjamin L. Ebert for the kind donation of HEK-293T-CRBN-KO and parental HEK-293T-CRBN-WT cells. We also thank David Martín-Gutiérrez, Lucía Rivera-Endrinal, Dr. Daniel García-Ovejero, Dr. Eduardo Molina-Holgado, and the personnel of the core microscopy centre, the genomics unit, and the animal facilities of Universidad Complutense de Madrid for their expert technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

  • Costas-Insua, Carlos
  • Hermoso-López, Alba
  • Moreno, Estefanía
  • Diez-Alarcia, Rebeca
  • Álvaro-Blázquez, Alicia
  • Maroto, Irene B.
  • Sanchez-Ruiz, A.
  • Blázquez, Cristina
  • Morales, Paula
  • Canela, Enric I.
  • Casadó, Vicent
  • Urigüen, Leyre
  • Perea, Gertrudis
  • Bellocchio, Luigi
  • Rodríguez-Crespo, Ignacio
  • Guzmán, Manuel
Cereblon/CRBN is a substrate-recognition component of the Cullin4A-DDB1-Roc1 E3 ubiquitin ligase complex. Destabilizing mutations in the human CRBN gene cause a form of autosomal recessive non-syndromic intellectual disability (ARNSID) that is modelled by knocking-out the mouse Crbn gene. A reduction in excitatory neurotransmission has been proposed as an underlying mechanism of the disease. However, the precise factors eliciting this impairment remain mostly unknown. Here we report that CRBN molecules selectively located on glutamatergic neurons are necessary for proper memory function. Combining various in vivo approaches, we show that the cannabinoid CB1 receptor (CB1R), a key suppressor of synaptic transmission, is overactivated in CRBN deficiency-linked ARNSID mouse models, and that the memory deficits observed in these animals can be rescued by acute CB1R-selective pharmacological antagonism. Molecular studies demonstrated that CRBN interacts physically with CB1R and impairs the CB1R-Gi/o-cAMP-PKA pathway in a ubiquitin ligase-independent manner. Taken together, these findings unveil that CB1R overactivation is a driving mechanism of CRBN deficiency-linked ARNSID and anticipate that the antagonism of CB1R could constitute a new therapy for this orphan disease., This work was supported by the Spanish Ministerio de Ciencia e Innovación (MICINN/FEDER; grants PID2021-125118OB-I00 to MG, PID2020-113938RB-I00 to EM and VC, PID2019-106579RB-I00 and PID2022-142617NB-I00 to GP, and PID2019-106404RB-I00 to LU), as well as by the Generalitat de Catalunya (grant 2021-SGR-00230 to EM and VC). LB was supported by INSERM. CC-Iand IBM were supported by contracts from the Spanish Ministerio de Universidades (Formación de Profesorado Universitario Program, referencesFPU16/02593 and FPU15/01833, respectively). CC-I was also supported by an EMBO short-term fellowship (reference STF-8930). We are indebted to Dr.Benjamin L. Ebert for the kind donation of HEK-293T-CRBN-KO and parental HEK-293T-CRBN-WT cells. We also thank David Martín-Gutiérrez, Lucía Rivera-Endrinal, Dr. Daniel García-Ovejero, Dr. Eduardo Molina-Holgado, and the personnel of the core microscopy centre, the genomics unit, and the animal facilities of Universidad Complutense de Madrid for their expert technical assistance.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

  • Costas-Insua, Carlos
  • Hermoso-López, Alba
  • Moreno, Estefanía
  • Montero-Fernández, Carlos
  • Álvaro-Blázquez, Alicia
  • Maroto, Irene B.
  • Sánchez-Ruiz, Andrea
  • Diez-Alarcia, Rebeca
  • Blázquez, Cristina
  • Morales, Paula
  • Canela, Enric I.
  • Casadó, Vicent
  • Urigüen, Leyre
  • Perea, Gertrudis
  • Bellocchio, Luigi
  • Rodríguez-Crespo, Ignacio
  • Guzmán, Manuel
Cereblon/CRBN is a substrate-recognition component of the Cullin4A-DDB1-Roc1 E3 ubiquitin ligase complex. Destabilizing mutations in the human CRBN gene cause a form of autosomal recessive non-syndromic intellectual disability (ARNSID) that is modelled by knocking-out the mouse Crbn gene. A reduction in excitatory neurotransmission has been proposed as an underlying mechanism of the disease. However, the precise factors eliciting this impairment remain mostly unknown. Here we report that CRBN molecules selectively located on glutamatergic neurons are necessary for proper memory function. Combining various in vivo approaches, we show that the cannabinoid CB1 receptor (CB1R), a key suppressor of synaptic transmission, is overactivated in CRBN deficiency-linked ARNSID mouse models, and that the memory deficits observed in these animals can be rescued by acute CB1R-selective pharmacological antagonism. Molecular studies demonstrated that CRBN interacts physically with CB1R and impairs the CB1R-Gi/o-cAMP-PKA pathway in a ubiquitin ligase-independent manner. Taken together, these findings unveil that CB1R overactivation is a driving mechanism of CRBN deficiency-linked ARNSID and anticipate that the antagonism of CB1R could constitute a new therapy for this orphan disease., This work was supported by the Spanish Ministerio de Ciencia e Innovación (MICINN/FEDER; grants PID2021-125118OB-I00 to MG, PID2020-113938RB-I00 to EM and VC, PID2019-106579RB-I00 and PID2022-142617NB-I00 to GP, and PID2019-106404RB-I00 to LU), as well as by the Generalitat de Catalunya (grant 2021-SGR-00230 to EM and VC). LB was supported by INSERM. CC-I and IBM were supported by contracts from the Spanish Ministerio de Universidades (Formación de Profesorado Universitario Program, references FPU16/02593 and FPU15/01833, respectively). CC-I was also supported by an EMBO short-term fellowship (reference STF-8930). We are indebted to Dr. Benjamin L. Ebert for the kind donation of HEK-293T-CRBN-KO and parental HEK-293T-CRBN-WT cells. We also thank David Martín-Gutiérrez, Lucía Rivera-Endrinal, Dr. Daniel García-Ovejero, Dr. Eduardo Molina-Holgado, and the personnel of the core microscopy centre, the genomics unit, and the animal facilities of Universidad Complutense de Madrid for their expert technical assistance., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Design of small non-peptidic ligands that alter heteromerization between cannabinoid CB1 and serotonin 5HT2A receptors

  • Matsoukas, Minos-Timotheos
  • Ciruela Jardí, Marc
  • Gallo, María, 1989-
  • Ferré, Sergi
  • Andreu Martínez, David
  • Casadó, Vicent
  • Pardo, Leonardo
  • Moreno, Estefanía
Activation of cannabinoid CB1 receptors (CB1R) by agonists induces analgesia but also induces cognitive impairment through the heteromer formed between CB1R and the serotonin 5HT2A receptor (5HT2AR). This side effect poses a serious drawback in the therapeutic use of cannabis for pain alleviation. Peptides designed from the transmembrane helices of CB1R, which are predicted to bind 5HT2AR and alter the stability of the CB1R-5HT2AR heteromer, have been shown to avert CB1R agonist-induced cognitive impairment while preserving analgesia. Using these peptides as templates, we have now designed nonpeptidic small molecules that prevent CB1R-5HT2AR heteromerization in bimolecular fluorescence complementation assays and the heteromerization-dependent allosteric modulations in cell signaling experiments. These results provide proof-of-principle for the design of optimized ligand-based disruptors of the CB1R-5HT2AR heteromer, opening new perspectives for in vivo studies., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (projects PID2020-113938RB-I00, PID2022-140912OB-I00, and PID2023-146914OB-I00) and Generalitat de Catalunya (2021-SGR-00230 and 2021-SGR-00304). S.F. is funded with the intramural funds of the National Institute on Drug Abuse (ZIA DA000493). Work at MELIS-UPF is supported by the MCIN “María de Maeztu” program for units of excellence in R&D (CEX2018-000792-M). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by the Barcelona Supercomputing Center (RES-BCV-2024-2-0002).